Cargando…

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer

PURPOSE: Extending adjuvant endocrine therapy (ET) beyond the standard 5 years offers added protection against late breast cancer recurrences in women with early-stage hormone receptor-positive (HR +) breast cancer. Little is known about treatment persistence to extended ET (EET) and the role that g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foldi, Julia, Tsagianni, Anastasia, Salganik, Max, Schnabel, Catherine A., Brufsky, Adam, van Londen, G. J., Pusztai, Lajos, Sanft, Tara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314405/ https://www.ncbi.nlm.nih.gov/pubmed/37391697 http://dx.doi.org/10.1186/s12885-023-11104-w

Ejemplares similares

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
por: Sanft, Tara, et al.
Publicado: (2015)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

Statins and endocrine resistance in breast cancer
por: Hyder, Tara, et al.
Publicado: (2021)

Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform
por: Eom, Kirsten Y., et al.
Publicado: (2021)

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
por: van Hellemond, Irene E. G., et al.
Publicado: (2018)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
por: Bekes, Inga, et al.
Publicado: (2023)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
por: Dieli-Conwright, Christina M., et al.
Publicado: (2022)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
por: Bartlett, J M S, et al.
Publicado: (2019)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
por: Sella, Tal, et al.
Publicado: (2023)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer
por: Wang, Wei, et al.
Publicado: (2016)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
por: Park, Ko Un, et al.
Publicado: (2021)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
por: Lambert, Leah K., et al.
Publicado: (2018)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
por: Licata, Luca, et al.
Publicado: (2023)

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer
por: Sim, Sung Hoon, et al.
Publicado: (2021)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
por: Iwamoto, Takayuki, et al.
Publicado: (2010)

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics
por: Shiang, Christine, et al.
Publicado: (2010)

Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
por: Kunst, Natalia, et al.
Publicado: (2020)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
por: Hara, Fumikata, et al.
Publicado: (2010)

Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer
por: Lee, Joo Yun, et al.
Publicado: (2018)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
por: Salvo, Elizabeth M., et al.
Publicado: (2021)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study
por: Sgroi, Dennis C., et al.
Publicado: (2016)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
por: Gao, Hong-Fei, et al.
Publicado: (2021)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ikql3om6e6u0h389645g8bnnk